How GLP‑1 weight‑loss medicines affect taste and eating habits
Official title: Changes in Taste Perception, Eating Habits, and Other Behavioral Aspects Associated With the Use of GLP-1 Receptor Agonists in Patients Undergoing Weight Loss Treatment: A Retrospective Observational Study.
Run by San Raffaele Telematic University · NCT07229170 · Data updated 2026-11-12
This project sees if adults with obesity who take GLP‑1 drugs for at least 12 weeks notice changes in taste, food preferences, and eating habits.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | San Raffaele Telematic University Academic / other |
| Locations | 4 sites (Roma, Italy and 3 other locations) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2028 |
| Registry record updated | April 28, 2026 |
| Trial ID | NCT07229170 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–60 with obesity who have been treated with GLP‑1 receptor agonists (e.g., semaglutide or tirzepatide) and have available pre‑ and post‑treatment clinical and dietary records at the participating centers are ideal candidates.
✕Probably not a fit
People outside the 18–60 age range, those without at least 12 weeks of documented GLP‑1 treatment data, or those with independent taste disorders or severe comorbidities are unlikely to benefit from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective observational analysis of adults aged 18–60 treated with GLP‑1 receptor agonists at specialized nutrition centers in Italy. Researchers extract anonymized clinical records, dietary questionnaires, bioimpedance body composition data, and metabolic measures from before and after at least 12 weeks of therapy with drugs such as semaglutide or tirzepatide. The primary focus is on changes in taste perception and food preferences, with secondary outcomes including weight, BMI, fat and lean mass, gastrointestinal side effects, physical activity, energy expenditure, and treatment adherence. Statistical comparisons use paired tests and regression models adjusted for age, sex, baseline BMI, diabetes status, and concomitant medications.
Why it matters
Potential benefit: If successful, the findings could help clinicians personalize counseling on food choices and manage side effects to improve adherence and weight‑loss outcomes.
How similar studies have gone: Prior clinical reports and trials have suggested GLP‑1 drugs can alter appetite and food preferences, but systematic retrospective analyses focused specifically on taste perception remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion: Adults aged 18-60 years diagnosed with obesity and undergoing treatment with GLP-1 receptor agonists such as semaglutide or tirzepatide. Must have clinical records and dietary data available for at least 12 weeks of treatment. Exclusion: Patients with conditions affecting taste independent of GLP-1 treatment, severe comorbidities, or inability to provide consent and data.
Where it's running
-
San Raffaele Open University
Roma, Italy, Italy Recruiting -
Department for the Promotion of Human Science and Quality of Life San Raffaele Open University
Rome, Italy Recruiting -
San Raffaele Open University
Rome, Italy Recruiting -
San Raffaele Open University
Rome, Italy Active not recruiting
Study contacts
- Study coordinator: Mauro Lombardo, MD
- Email: mauro.lombardo@uniroma5.it
- Phone: +393899740197
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized 26-week program to help keep weight off
This 26-week program tests whether tailored messages, weekly check-ins and weighing, and optional health coaching help adults who recently lost at least 7% of their weight keep it off.
-
How incretin treatments affect muscle mass and function in people with overweight or obesity
This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.
-
Dose find for remimazolam plus alfentanil for gastroscopy in obese adults
This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.
-
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults
This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.
-
Gut barrier and inflammation after fast-food overfeeding in adults
This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.
-
15-year outcomes after sleeve gastrectomy in France
This study looks at how people who had sleeve gastrectomy have fared over 15 years to see long-term weight changes and health effects.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.